New study below [1].
"The Mainsail trial was a multinational randomized phase 3 study of 1059 patients with mCRPC receiving docetaxel, prednisone, and lenalidomide (DPL) or docetaxel, prednisone, and a placebo (DP). Study patients were treated until progressive disease or unacceptable adverse effects occurred. Median {overall survival} was found to be inferior in the DPL arm compared with the DP arm. As a result of increased toxic effects with the DPL combination, patients on DPL received fewer docetaxel cycles (median, 6) vs 8 cycles in the control group."
"Treatment with 8 or more cycles of docetaxel was associated with superior {overall survival} (hazard ratio [HR], 1.909 ...), irrespective of lenalidomide treatment (HR, 1.060 ...)."
"Likewise, in the sensitivity analysis, patients who received a greater number of docetaxel cycles had superior {overall survival}; patients who received more than 10 cycles had a median {overall survival} of 33.0 months compared with 26.9 months in patients treated with 8 to 10 cycles; and patients who received 5 to 7 cycles had a median {overall survival} of 22.8 months"
...
In a Hong Kong study from 2015 [2]:
"In multivariate analysis, eight cycles or more of chemotherapy [hazard ratio (HR) = 0.151 ... {was an} ... independent determinant of {overall survival}."
However, in a 2012 analysis of the TAX-327 & CS-205 trial [3]:
"A survival benefit was not detected with >10 cycles of {docetaxel plus prednisone} in men with mCRPC in this retrospective hypothesis-generating analysis."
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/275...
